Fazarabine: A report of response in a patient with multiply relapsed embryonal cell carcinoma

P. G. Johnston, D. Kleiner, K. H. Cowan

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

This report describes a patient with multiply relapsed and advanced metastatic embryonal cell carcinoma who achieved a pathological partial remission (PR) following treatment with a Phase I chemotherapeutic agent, arabinosyl-5-azacytosine (Ara-AC), followed by orchiectomy. The antimetabolic Ara-AC is worthy of further study in patients with germ-cell tumors. It would appear that the antimetabolite Ara-AC may have significant activity in patients with germ-cell tumors.

Original languageEnglish (US)
Pages (from-to)34-37
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume16
Issue number1
DOIs
StatePublished - Jan 1 1993

Fingerprint

fazarabine
Embryonal Carcinoma Stem Cells
Germ Cell and Embryonal Neoplasms
Antimetabolites
Orchiectomy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Fazarabine : A report of response in a patient with multiply relapsed embryonal cell carcinoma. / Johnston, P. G.; Kleiner, D.; Cowan, K. H.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 16, No. 1, 01.01.1993, p. 34-37.

Research output: Contribution to journalArticle

@article{0b33aecef9cc46cf8a95781c853f95b6,
title = "Fazarabine: A report of response in a patient with multiply relapsed embryonal cell carcinoma",
abstract = "This report describes a patient with multiply relapsed and advanced metastatic embryonal cell carcinoma who achieved a pathological partial remission (PR) following treatment with a Phase I chemotherapeutic agent, arabinosyl-5-azacytosine (Ara-AC), followed by orchiectomy. The antimetabolic Ara-AC is worthy of further study in patients with germ-cell tumors. It would appear that the antimetabolite Ara-AC may have significant activity in patients with germ-cell tumors.",
author = "Johnston, {P. G.} and D. Kleiner and Cowan, {K. H.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1097/00000421-199302000-00009",
language = "English (US)",
volume = "16",
pages = "34--37",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Fazarabine

T2 - A report of response in a patient with multiply relapsed embryonal cell carcinoma

AU - Johnston, P. G.

AU - Kleiner, D.

AU - Cowan, K. H.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - This report describes a patient with multiply relapsed and advanced metastatic embryonal cell carcinoma who achieved a pathological partial remission (PR) following treatment with a Phase I chemotherapeutic agent, arabinosyl-5-azacytosine (Ara-AC), followed by orchiectomy. The antimetabolic Ara-AC is worthy of further study in patients with germ-cell tumors. It would appear that the antimetabolite Ara-AC may have significant activity in patients with germ-cell tumors.

AB - This report describes a patient with multiply relapsed and advanced metastatic embryonal cell carcinoma who achieved a pathological partial remission (PR) following treatment with a Phase I chemotherapeutic agent, arabinosyl-5-azacytosine (Ara-AC), followed by orchiectomy. The antimetabolic Ara-AC is worthy of further study in patients with germ-cell tumors. It would appear that the antimetabolite Ara-AC may have significant activity in patients with germ-cell tumors.

UR - http://www.scopus.com/inward/record.url?scp=0027396073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027396073&partnerID=8YFLogxK

U2 - 10.1097/00000421-199302000-00009

DO - 10.1097/00000421-199302000-00009

M3 - Article

C2 - 7678714

AN - SCOPUS:0027396073

VL - 16

SP - 34

EP - 37

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -